Improving Scale-Up Starts With Expression Strategy

Scale-up failures are frequently attributed to process engineering challenges, but the roots often trace back to earlier decisions around expression strategy. Diane Retallack, PhD, President and COO of Primrose Bio, brings over 25 years of experience in molecular biology, protein expression, and strain engineering to a focused examination of how expression system choices made at the outset of development shape what becomes possible, or problematic, at larger scales.

Drawing on her background establishing the Pfenex Expression Technology platform and guiding therapeutic programs from conception through commercialization, Retallack addresses the upstream decisions that carry the most consequence for scale-up performance. Explore the on-demand session below to learn how expression screening can sharpen development decisions before significant investment is committed.